Wedbush Reiterates “Outperform” Rating for Zura Bio (NASDAQ:ZURA)

Zura Bio (NASDAQ:ZURA)‘s stock had its “outperform” rating restated by investment analysts at Wedbush in a report issued on Wednesday,Benzinga reports. They currently have a $15.00 target price on the stock. Wedbush’s price objective suggests a potential upside of 184.95% from the stock’s previous close.

A number of other analysts have also recently commented on the stock. Oppenheimer dropped their price target on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Friday, March 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a report on Wednesday, April 8th. Finally, Chardan Capital increased their target price on Zura Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, March 23rd. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $10.75.

Zura Bio Price Performance

Shares of ZURA traded down $0.64 during mid-day trading on Wednesday, hitting $5.26. The stock had a trading volume of 164,089 shares, compared to its average volume of 832,263. Zura Bio has a 52 week low of $1.06 and a 52 week high of $7.44. The business has a fifty day moving average price of $4.47 and a 200-day moving average price of $5.29. The firm has a market cap of $499.45 million, a P/E ratio of -5.00 and a beta of 0.03.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.05). As a group, research analysts expect that Zura Bio will post -0.76 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ZURA. Allworth Financial LP purchased a new stake in shares of Zura Bio in the fourth quarter worth $30,000. Scientech Research LLC bought a new stake in Zura Bio during the third quarter valued at $45,000. AQR Capital Management LLC purchased a new position in Zura Bio during the first quarter worth about $72,000. Bank of America Corp DE grew its position in Zura Bio by 31.9% during the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after buying an additional 9,966 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in Zura Bio in the 3rd quarter worth about $109,000. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.